Identification of cytochrome P450 3A4 modification site with reactive metabolite using linear ion trap-fourier transform mass spectrometry

Chemical Research in Toxicology

Volumn 20, Issue 10, 2007, Pages 1373-1378

  Yukinaga, Hideo ^a   Takami, Tomonori ^b   Shioyama, Sho Hei ^b   Tozuka, Zenzaburo ^b   Masumoto, Hiroshi ^a   Okazaki, Osamu ^a   Sudo, Ken Ichi ^a  

^a DAIICHI SANKYO CO   (Japan)

^b JCL Bioassay Corporation   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; PEPTIDE; RALOXIFENE; UNCLASSIFIED DRUG; VALYLTRYPTOPHYLGLYCYLPHENYLALANYLTYROSYLASPARTYLGLYCYLGLUTAMINYL GLUTAMINYLPROLYLVALYLLEUCYLALANYLISOLEUCYLTHREONYLASPARTYLPROLYLASPARTYL METHIONYLISOLEUCYLLYSINE;

ARTICLE; CYCLOTRON; DRUG BINDING SITE; FOURIER TRANSFORM MASS SPECTROMETRY; ION TRAP MASS SPECTROMETRY; NANOANALYSIS; PROTEIN ANALYSIS; PROTEIN MODIFICATION; PROTEOMICS; TOXICOKINETICS;

AMINO ACID SEQUENCE; BINDING SITES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; HUMANS; MOLECULAR SEQUENCE DATA; NANOTECHNOLOGY; PROTEIN STRUCTURE, QUATERNARY; PROTEOMICS; RALOXIFENE; SEQUENCE ANALYSIS, PROTEIN; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 35848962726     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx700165q     Document Type: Article

References (22)

1. Rendic, S. (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev. 34, 83-448.
2. Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., and Baillie, T. A. (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17, 3-16.
3. Dresser, G. K., Spence, J. D., and Bailey, D. G. (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 38, 41-57.
4. Zhou, S., Chan, E., Duan, W., Huang, M., and Chen, Y. Z. (2005) Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab. Rev. 37, 41-213.
5. Atkinson, A., Kenny, J. R., and Grime, K. (2005) Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab. Dispos. 33, 1637-1647.
6. Kent, U. M., Lin, H. L., Mills, D. E., Regal, K. A., and Hollenberg, P. F. (2006) Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6. Chem. Res. Toxicol. 19, 279-287.
7. He, K., Falick, A. M., Chen, B., Nilsson, F., and Correia, M. A. (1996) Identification of the heme adduct and an active site peptide modified during mechanism-based inactivation of rat liver cytochrome P450 2B1 by secobarbital. Chem. Res. Toxicol. 9, 614-622.
8. Roberts, E. S., Hopkins, N. E., Zaluzec, E. J., Gage, D. A., Alworth, W. L., and Hollenberg, P. F. (1994) Identification of active-site peptides from 3H-labeled 2-ethynylnaphthalene-inactivated P450 2B1 and 2B4 using amino acid sequencing and mass spectrometry. Biochemistry 33, 3766-3771.
9. Lightning, L. K., Jones, J. P., Friedberg, T., Pritchard, M. P., Shou, M., Rushmore, T. H., and Trager, W. F. (2000) Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394. Biochemistry 39, 4276-4287.
10. Alvarez-Diez, T. M., and Zheng, J. (2004) Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol. Chem. Res. Toxicol. 17, 150-157.
11. Roberts, E. S., Alworth, W. L., and Hollenberg, P. F. (1998) Mechanism-based inactivation of cytochromes P450 2E1 and 2B1 by 5-phenyl-1-pentyne. Arch. Biochem. Biophys. 354, 295-302.
12. Regal, K. A., Schrag, M. L., Kent, U. M., Wienkers, L. C., and Hollenberg, P. F. (2000) Mechanism-based inactivation of cytochrome P450 2B1 by 7-ethynylcoumarin: verification of apo-P450 adduction by electrospray ion trap mass spectrometry. Chem. Res. Toxicol. 13, 262-270.
13. Hutzler, J. M., Steenwyk, R. C., Smith, E. B., Walker, G. S., and Wienkers, L. C. (2004) Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]4-[4-(trifluoromethyl)-2-pyridinyl] piperazine: kinetic characterization and evidence for apoprotein adduction. Chem. Res. Toxicol. 17, 174-184.
14. Blobaum, A. L., Kent, U. M., Alworth, W. L., and Hollenberg, P. F. (2002) Mechanism-based inactivation of cytochromes P450 2E1 and 2E1 T303A by tert-butyl acetylenes: characterization of reactive intermediate adducts to the heme and apoprotein. Chem. Res. Toxicol. 15, 1561-1571.
15. Kent, U. M., Roberts-Kirchhoff, E. S., Moon, N., Dunham, W. R., and Hollenberg, P. F. (2001) Spectral studies of tert-butyl isothiocyanate- inactivated P450 2E1. Biochemistry 40, 7253-7261.
16. Koenigs, L. L., Peter, R. M., Hunter, A. P., Haining, R. L., Rettie, A. E., Friedberg, T., Pritchard, M. P., Shou, M., Rushmore, T. H., and Trager, W. F. (1999) Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9. Biochemistry 38, 2312-2319.
17. Bateman, K. P., Baker, J., Wilke, M., Lee, J., Leriche, T., Seto, C., Day, S., Chauret, N., Quellet, M., and Nicoll-Griffith, D. A. (2004) Detection of covalent adducts to cytochrome P450 3A4 using liquid chromatography mass spectrometry. Chem. Res. Toxicol. 17, 1356-1361.
18. Chen, Q., Ngui, J. S., Doss, G. A., Wang, R. W., Cai, X., DiNinno, F. P., Blizzard, T. A., Hammond, M. L., Stearns, R. A., Evans, D. C., Baillie, T. A., and Tang, W. (2002) Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem. Res. Toxicol. 15, 907-914.
19. Baer, B. R., Wienkers, L. C., and Rock, D. A. (2007) Time-Dependent Inactivation of P450 3A4 by Raloxifene: Identification of Cys239 as the Site of Apoprotein Alkylation. Chem. Res. Toxicol. 20, 954-964.
20. Wen, B., Doneanu, C. E., Gartner, C. A., Roberts, A. G., Atkins, W. M., and Nelson, S. D. (2005) Fluorescent photoaffinity labeling of cytochrome P450 3A4 by lapachenole: identification of modification sites by mass spectrometry. Biochemistry 44, 1833-1845.
21. Yano, J. K., Wester, M. R., Schoch, G. A., Griffin, K. J., Stout, C. D., and Johnson, E. F. (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J. Biol. Chem. 279, 38091-38094.
22. Ekroos, M., and Sjogren, T. (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc. Natl. Acad. Sci. U.S.A. 103, 13682-13687.